Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension

被引:75
作者
Eddahibi, S
Humbert, M
Fadel, E
Raffestin, B
Darmon, M
Capron, F
Simonneau, G
Dartevelle, P
Hamon, M
Adnot, S [1 ]
机构
[1] Fac Med Creteil, Dept Physiol, INSERM U492, F-94010 Creteil, France
[2] Hop Henri Mondor, AP HP, Dept Physiol, F-94010 Creteil, France
[3] Hop Antoine Beclere, AP HP, Serv Pneumol, UPRES EA2705, Clamart, France
[4] Hop Marie Lannelongue, UPRES EA2705, Serv Chirurg Thorac Vasc & Transplantat Cardiopul, F-92350 Le Plessis Robinson, France
[5] Univ Paris 05, Dept Physiol, Hop Ambroise Pare, Boulogne, France
[6] Univ Paris 06, INSERM U288, Paris, France
关键词
D O I
10.1172/JCI12805
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Hyperplasia of pulmonary artery smooth muscle cells (PA-SMCs) is a hallmark pathological feature of primary pulmonary hypertension (PPH). Here we found that PA-SMCs from patients with PPH grow faster than PA-SMCs from controls when stimulated by serotonin or serum and that these effects are due to increased expression of the serotonin transporter (5-HTT), which mediates internalization of indoleamine. In the presence of 5-HTT inhibitors, the growth stimulatory effects of serum and serotonin were markedly reduced and the difference between growth of PA-SMCs from patients and controls was no longer observed. As compared with controls, the expression of 5-HTT was increased in cultured PA-SMCs as well as in platelets and lungs from patients with PPH where it predominated in the media of thickened pulmonary arteries and in onion-bulb lesions. The L-allelic variant of the 5HTT gene promoter, which is associated with 5-HTT overexpression and increased PA-SMC growth, was present in homozygous form in 65% of patients but in only 27% of controls. We conclude that 5-HTT activity plays a key role in the pathogenesis of PA-SMC proliferation in PPH and that a 5HTT polymorphism confers susceptibility to PPH.
引用
收藏
页码:1141 / 1150
页数:10
相关论文
共 31 条
[1]   Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].
Abenhaim, L ;
Moride, Y ;
Brenot, F ;
Rich, S ;
Benichou, J ;
Kurz, X ;
Higenbottam, T ;
Oakley, C ;
Wouters, E ;
Aubier, M ;
Simonneau, G ;
Begaud, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616
[2]   SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION [J].
CHOMCZYNSKI, P ;
SACCHI, N .
ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) :156-159
[3]   Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene [J].
Deng, ZM ;
Morse, JH ;
Slager, SL ;
Cuervo, N ;
Moore, KJ ;
Venetos, G ;
Kalachikov, S ;
Cayanis, E ;
Fischer, SG ;
Barst, RJ ;
Hodge, SE ;
Knowles, JA .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (03) :737-744
[4]  
Eddahibi S, 1999, AM J RESP CRIT CARE, V159, pA165
[5]   Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene [J].
Eddahibi, S ;
Hanoun, N ;
Lanfumey, L ;
Lesch, KP ;
Raffestin, B ;
Hamon, M ;
Adnot, S .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (11) :1555-1562
[6]   Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells - Relationship with the mitogenic action of serotonin [J].
Eddahibi, S ;
Fabre, V ;
Boni, C ;
Martres, MP ;
Raffestin, B ;
Hamon, M ;
Adnot, S .
CIRCULATION RESEARCH, 1999, 84 (03) :329-336
[7]  
Eddahibi S, 2001, J PHARMACOL EXP THER, V297, P148
[8]  
EDDAHIBI S, 1997, AM J PHYSIOL, V275, pH1773
[9]   Aminorex to fen/phen - An epidemic foretold [J].
Fishman, AP .
CIRCULATION, 1999, 99 (01) :156-161
[10]  
Frid MG, 1997, CIRC RES, V81, P940